LG Life Sciences
As of the edition of 20 October 2026, LG Life Sciences runs 7 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
LG Life Sciences was merged.
- LG Life Sciences: merged
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Went quiet | 3 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Gemifloxacin | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Nutrition and metabolism: 10 trials led
- Hormones: 9 trials led
- Infections: 6 trials led